Dose-response relationship of insulin glulisine in subjects with type 1 diabetes
| Autor: | L. Teichert, Leszek Nosek, A. D. Frick, K. Rave, Lutz Heinemann, Reinhard H.A. Becker |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Insulin glulisine
medicine.medical_specialty Type 1 diabetes business.industry Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment Serum concentration medicine.disease Dose–response relationship Endocrinology Internal medicine Diabetes mellitus Internal Medicine medicine Glycosylated haemoglobin business Body mass index medicine.drug |
| Zdroj: | Diabetes, Obesity and Metabolism. 11:60-68 |
| ISSN: | 1463-1326 1462-8902 |
| DOI: | 10.1111/j.1463-1326.2008.01013.x |
| Popis: | Aim: Little is known about the dose–response relationships of rapid-acting insulin analogues in subjects with diabetes. This study compared the dose–exposure and dose–response relationships of insulin glulisine and regular human insulin (RHI) in subjects with type 1 diabetes. Methods: Eighteen male subjects with type 1 diabetes (mean glycosylated haemoglobin, HbA1c, 7.7%; body mass index 24.5 kg/m2) received subcutaneous injections of insulin glulisine followed by RHI (both at doses of 0.075, 0.15 and 0.3 U/kg) in the same three-way crossover, randomized order in a euglycaemic glucose-clamp study. Results: Insulin glulisine and RHI showed dose-proportional increases in exposure (INS-AUCtotal) and maximum serum concentration (INS-Cmax) in the dose ranges 0.075, 0.15 and 0.3 U/kg. At all doses, within 2 h after injection, about twice as much insulin glulisine was absorbed as RHI (INS-AUC0–2h: 3855, 6832 and 13237 vs. 2356, 3630 and 6231 μU.min/mL; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text